BM findings according to the age, disease stage, and cytogenetic aberrations of the primary tumor of 41 NB patients identified by the automatic microscopic procedure
| Tumor cell positivity was stated when the tumor typical cytogenetic aberrations were found in at least two GD2 immunolabeled cells by a targeted sequential FISH analysis after automatic repositioning (GD2+/FISH+). . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Agea . | Disease stage . | Genetic aberration in the primary tumor . | No. of punction . | GD2+ samples . | GD2+/FISH+ samples . | ||||||
| 1 | 9 m | 1 | del1p | 4 | 0 | 0 | ||||||
| 2 | 4 y | 1 | Trisomy 1 and 2 | 2 | 0 | 0 | ||||||
| 3 | 13 m | 1 | Pentasomy 1 | 4 | 2 | 0 | ||||||
| 4 | 3 m | 2B | Trisomy 1 and 2 | 4 | 0 | 0 | ||||||
| 5 | 11 m | 2B | del1p | 2 | 0 | 0 | ||||||
| 6 | 11 m | 2B | imb1p, 17q gain | 4 | 3 | 0 | ||||||
| 7 | 4 y | 3 | 17q gain | 1 | 0 | 0 | ||||||
| 8 | 10 m | 3 | Trisomy 1 and 2 | 4 | 0 | 0 | ||||||
| 9 | 4 y | 3 | n.t.b | 4 | 0 | 0 | ||||||
| 10 | 11 m | 3 | Tri- and hexasomy 1 and 2 | 2 | 0 | 0 | ||||||
| 11 | 3 y | 3 | MYCN ampl | 4 | 3 | 0 | ||||||
| 12 | 12 m | 3 | 17q gain | 4 | 3 | 0 | ||||||
| 13 | 3 y | 3 | del1p, MYCN ampl | 4 | 4 | 0 | ||||||
| 14 | 2 y | 4 | Tri- and tetrasomy 1 and 2 | 4 | 4 | 4 | ||||||
| 15 | 3 y | 4 | 17q gain | 2 | 2 | 2 | ||||||
| 16 | 12 y | 4 | 17q gain | 1 | 1 | 1 | ||||||
| 17 | 2 y | 4 | 17q gain | 1 | 1 | 1 | ||||||
| 18 | 2 y | 4 | imb1p | 4 | 4 | 4 | ||||||
| 19 | 6 y | 4 | del1p | 4 | 4 | 4 | ||||||
| 20 | 12 y | 4 | del1p | 4 | 4 | 4 | ||||||
| 21 | 8 m | 4 | del1p | 2 | 2 | 2 | ||||||
| 22 | 4 y | 4 | imb1p | 1 | 1 | 1 | ||||||
| 23 | 15 m | 4 | del1p, MYCN ampl | 3 | 3 | 3 | ||||||
| 24 | 14 m | 4 | del1p, MYCN ampl | 4 | 0 | 0 | ||||||
| 25 | 3 y | 4 | del1p, gain MYCN | 2 | 2 | 2 | ||||||
| 26 | 2 y | 4 | del1p, MYCN ampl | 1 | 1 | 1 | ||||||
| 27 | 3 y | 4 | del1p, gain MYCN | 1 | 1 | 1 | ||||||
| 28 | 4 y | 4 | del1p, MYCN ampl, 17q gain | 2 | 2 | 2 | ||||||
| 29 | 2 y | 4 | del1p, MYCN ampl, 17q gain | 1 | 1 | 1 | ||||||
| 30 | 4 y | 4 | imb1p, MYCN ampl, 17q gain | 4 | 3 | 3 | ||||||
| 31 | 5 y | 4 | del1p, MYCN ampl, 17q gain | 4 | 4 | 4 | ||||||
| 32 | 18 m | 4 | imb1p, MYCN ampl, 17q gain | 4 | 3 | 3 | ||||||
| 33 | 5 y | 4 | del1p, MYCN ampl, 17q gain | 1 | 1 | 1 | ||||||
| 34 | 2 y | 4 | del1p, MYCN ampl, 17q gain | 1 | 1 | 1 | ||||||
| 35 | 2 m | 4s | Trisomy 1 | 4 | 3 | 3 | ||||||
| 36 | 1 m | 4s | Trisomy 1 | 4 | 3 | 3 | ||||||
| 37 | 10 m | 4s | Trisomy 1 and 2 | 4 | 4 | 4 | ||||||
| 38 | 4 m | 4s | Trisomy 1 and 2 | 2 | 2 | 2 | ||||||
| 39 | 5 m | 4s | Tetrasomy 1 | 3 | 1 | 1 | ||||||
| 40 | 13 m | 4s | Tri- and tetrasomy 17 | 4 | 4 | 4 | ||||||
| Tumor cell positivity was stated when the tumor typical cytogenetic aberrations were found in at least two GD2 immunolabeled cells by a targeted sequential FISH analysis after automatic repositioning (GD2+/FISH+). . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Agea . | Disease stage . | Genetic aberration in the primary tumor . | No. of punction . | GD2+ samples . | GD2+/FISH+ samples . | ||||||
| 1 | 9 m | 1 | del1p | 4 | 0 | 0 | ||||||
| 2 | 4 y | 1 | Trisomy 1 and 2 | 2 | 0 | 0 | ||||||
| 3 | 13 m | 1 | Pentasomy 1 | 4 | 2 | 0 | ||||||
| 4 | 3 m | 2B | Trisomy 1 and 2 | 4 | 0 | 0 | ||||||
| 5 | 11 m | 2B | del1p | 2 | 0 | 0 | ||||||
| 6 | 11 m | 2B | imb1p, 17q gain | 4 | 3 | 0 | ||||||
| 7 | 4 y | 3 | 17q gain | 1 | 0 | 0 | ||||||
| 8 | 10 m | 3 | Trisomy 1 and 2 | 4 | 0 | 0 | ||||||
| 9 | 4 y | 3 | n.t.b | 4 | 0 | 0 | ||||||
| 10 | 11 m | 3 | Tri- and hexasomy 1 and 2 | 2 | 0 | 0 | ||||||
| 11 | 3 y | 3 | MYCN ampl | 4 | 3 | 0 | ||||||
| 12 | 12 m | 3 | 17q gain | 4 | 3 | 0 | ||||||
| 13 | 3 y | 3 | del1p, MYCN ampl | 4 | 4 | 0 | ||||||
| 14 | 2 y | 4 | Tri- and tetrasomy 1 and 2 | 4 | 4 | 4 | ||||||
| 15 | 3 y | 4 | 17q gain | 2 | 2 | 2 | ||||||
| 16 | 12 y | 4 | 17q gain | 1 | 1 | 1 | ||||||
| 17 | 2 y | 4 | 17q gain | 1 | 1 | 1 | ||||||
| 18 | 2 y | 4 | imb1p | 4 | 4 | 4 | ||||||
| 19 | 6 y | 4 | del1p | 4 | 4 | 4 | ||||||
| 20 | 12 y | 4 | del1p | 4 | 4 | 4 | ||||||
| 21 | 8 m | 4 | del1p | 2 | 2 | 2 | ||||||
| 22 | 4 y | 4 | imb1p | 1 | 1 | 1 | ||||||
| 23 | 15 m | 4 | del1p, MYCN ampl | 3 | 3 | 3 | ||||||
| 24 | 14 m | 4 | del1p, MYCN ampl | 4 | 0 | 0 | ||||||
| 25 | 3 y | 4 | del1p, gain MYCN | 2 | 2 | 2 | ||||||
| 26 | 2 y | 4 | del1p, MYCN ampl | 1 | 1 | 1 | ||||||
| 27 | 3 y | 4 | del1p, gain MYCN | 1 | 1 | 1 | ||||||
| 28 | 4 y | 4 | del1p, MYCN ampl, 17q gain | 2 | 2 | 2 | ||||||
| 29 | 2 y | 4 | del1p, MYCN ampl, 17q gain | 1 | 1 | 1 | ||||||
| 30 | 4 y | 4 | imb1p, MYCN ampl, 17q gain | 4 | 3 | 3 | ||||||
| 31 | 5 y | 4 | del1p, MYCN ampl, 17q gain | 4 | 4 | 4 | ||||||
| 32 | 18 m | 4 | imb1p, MYCN ampl, 17q gain | 4 | 3 | 3 | ||||||
| 33 | 5 y | 4 | del1p, MYCN ampl, 17q gain | 1 | 1 | 1 | ||||||
| 34 | 2 y | 4 | del1p, MYCN ampl, 17q gain | 1 | 1 | 1 | ||||||
| 35 | 2 m | 4s | Trisomy 1 | 4 | 3 | 3 | ||||||
| 36 | 1 m | 4s | Trisomy 1 | 4 | 3 | 3 | ||||||
| 37 | 10 m | 4s | Trisomy 1 and 2 | 4 | 4 | 4 | ||||||
| 38 | 4 m | 4s | Trisomy 1 and 2 | 2 | 2 | 2 | ||||||
| 39 | 5 m | 4s | Tetrasomy 1 | 3 | 1 | 1 | ||||||
| 40 | 13 m | 4s | Tri- and tetrasomy 17 | 4 | 4 | 4 | ||||||